secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0000950170-24-127964
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharmaceuticals appoints Heather Turner to board; Ann Taylor resigns
--------------------------------------------------------------------------

- Heather Turner, former CEO of Carmot Therapeutics, appointed to Board of Directors effective Nov 18.
- Ann Taylor resigned effective Nov 18; departure not due to any disagreement with company operations.
- Turner brings 25 years biotech experience; led Carmot's $3.1B acquisition by Roche.
- Turner also appointed to Audit Committee; eligible for standard non-employee director compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017024127964/0000950170-24-127964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017024127964/tern-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer